Amphotericin B

Colistimethate sodium is a prodrug of colistin, which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and especially Pseudomonas aeruginosa.

Indication: U...

Daptomycin is a lipopeptide antibacterial agent active against Gram-positive bacteria.

Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of Gram-positive bacteria such as Staphylococcus aureu...

Micafungin is a semisynthetic lipopeptide from the echinocandin class of antifungal agents. Micafungin is active against most isolates of the following Candida species such as Candida albicans, Candida glabrata, Candida guiliermondii, Candida krusei, Candida parapsilosis and Candida tropicalis.
...

Polymyxin B is a mixture of the sulfates of polypeptide antibiotics active against Gram-negative bacteria.

Indication: Used in the treatment of patients with acute urinary, meningeal or blood-stream infections due to susceptible strains such as Pseudomonas aeruginosa,...

Vancomycin hydrochloride (HCI) is a glycopeptide antibiotic active against a wide variety of aerobic Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against dipht...

Voriconazole is a broad spectrum triazole antifungal agent.

Indication: Used in the treatment of patients with progressive, possibly life-threatening fungal infections such as candidaemia in non-neutropenic patients, invasive candidiasis in skin, abdomen, kidney, bladder ...

Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.

Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants for the tr...

Bacitracin zinc is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci. The zinc complex adds stability to the component, making bacitracin zinc more stable compared to bacitracin.

Indication: Used in the treatment...

Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Indi...

Colistin sulfate is a mixture of sulfates of polypeptide antibiotics active against Gram-negative bacteria including Pseudomonas aeruginosa, Enterobacter aerogenes, Escherichia coli and Klebsiella pneumoniae.

Indication: Used in the treatment of acute infections due...

Daptomycin is a lipopeptide antibiotic active against Gram-positive bacteria such as Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolate...

Gramicidin is a mixture of linear polypeptides active against a variety of Gram-positive bacteria.

Indication: Ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria, such as...

Copenhagen, Denmark, and Buffalo Grove, Illinois, US, 17 August 2021 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announces that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.

Committed to patients in a year impacted by COVID-19During 2020, our main focus was on maintaining full production and reliable supply of Xellia’s critical care products, while also ensuring the safety of our employees.


Read more in Xellia's Corporate Report 2020

Cleveland site to manufacture Xellia's aseptic injectables for the US market

Copenhagen, Denmark, 26 March 2020 - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has received inspection sign-off from the US Food and Drug Administration (FDA) enabling the Company to commence manufacturing of drug products at its Cleveland, Ohio site.

Xellia Pharmaceuticals operates internationally, with sales offices and production sites found across the globe. Xellia Pharmaceuticals is the leading supplier of important anti-infectives vancomycin, colistimethate sodium and daptomycin. We are vertically integrated from Active Pharmaceutical Ingredients (APIs) to Finished Dosage Forms (FDFs), with 150+ research and development scientists, and robust production sites.

Xellia Pharmaceuticals Opens New Commercial Office in Dubai

We are pleased to share the podcast: Molecule to Market – featuring our CEO, Carl-Åke Carlsson. The host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl-Åke, covering Xellia’s journey from an API supplier to a global specialty pharmaceutical company; producing anti-infective treatments. Carl‑Åke speaks about his journey from his position in finance to CEO and the transformation of Xellia as a company over the years; offering advice and insight from his experiences. Molecule to Market is sponsored and funded by Ramarketing, an international content, design and digital agency. Click the link here to access the podcast: https://apple.co/32a0RW0 or at https://spoti.fi/3jXjgLS